Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Blood Test Could Cut Hospital Stays for Children with Cancer

By LabMedica International staff writers
Posted on 21 Mar 2022

High temperatures are common in children undergoing treatment for cancer due to their lowered immune system. More...

The commonest approach is to keep children in hospital for up to a week while antibiotics are administered in case the fever is a symptom of a serious infection like sepsis. A new blood test could help to safely cut hospital stays for children with cancer who develop a fever, according to a new study.

The study, by researchers from the University of York (York, UK) and Hull York Medical School (York, UK) reveals the blood test can help doctors to distinguish between children whose fever is a sign of serious illness and those who are safe to go home. The results of the study, which involved 28 children with cancer, show that using the blood test in combination with a new protocol to identify children that are safe to go home, cuts their average stay in hospital down to two days, with some able to leave in as little as eight hours. The researchers believe that this change will make an enormous difference to children with cancer and their families, easing mental health and financial burdens. The test diagnoses serious infections by looking at levels of the biomarker procalcitonin in the blood. Those children with low levels often had their antibiotics stopped more quickly and went home earlier.

"Frequent fevers are a distressing and sometimes life-threatening complication of childhood cancer. Our study shows that procalcitonin blood tests could make a big difference to children who don’t have a serious infection, allowing them to go home earlier to be with their families, cutting unnecessary treatment with antibiotics and reducing an already intense mental and physical toll," said Dr. Bob Phillips from the Centre for Reviews and Dissemination at the University of York and Hull York Medical School. "These promising results and the willingness of families to take part in this research mean we can now apply for further funding in order to carry out a large-scale study."

Related Links:
University of York 
Hull York Medical School 


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.